Interleukin-10 gene polymorphism in COVID-19 patients and outcome of disease

ABSTRACT

More than 2 years into the COVID-19 pandemic with more than 6 million death worldwide, a dysregulated immune response to the pathogen associated with super-activation of pro-inflammatory cytokines, which may cause tissue injury, particularly lung tissue, IL-10 levels can impact on the clinical performance of the patients. this search conducted to detect the effect of Interleukin-10 gene polymorphisms on severity and outcome COVID-19 patients. A case - control study design for 120 COVID-19 patients that divided into sever, critical and moderate/mild patients in addition to 60 healthy subjects as control group to compare IL-10 serum level by ELISA technique and IL-10 gene polymorphism by ARMS-PCR assay. The result illustrated that 120 patients with covid-19 disease m classified as Critical cases 33 (27.5%), sever 42 (35%) and Mild/Moderate were 45 (37.5%). IL-10 increased in the serum of Covid-19 pneumonia patient's to (48.76 ± 12.3) pg / ml in compared with healthy controls (5.47±1.33) pg/ml. genotype results revealed that IL-10 gene distribution was GG homozygous (58.3%) higher in Covid-19 patients in compared to healthy controls (21.7)% and G allele was 124 for patient and 42 for healthy, so GG consider risk factor for coronavirus while AA genotype regard protective factor with frequency reach to 12% in patients and 48.3 % in healthy. The genotype distribution for critical/sever revealed the GG was 74.7% while in M/M was 31.1%. In conclusion: a significant association of GG genotype and allele G was observed with severity of COVID-19 infection.